Achieve Life Sciences (ACHV) announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical ...

Achieve Life Sciences, Inc. announced promising results from its ORCA-3 clinical trial of cytisinicline for smoking cessation, published in JAMA Internal Medicine. This Phase 3 study involved 792 ...

ORCA-3 was the second randomized, placebo-controlled Phase 3 clinical trial evaluating cytisinicline for smoking cessation in 792 U.S. adults. The authors concluded that ORCA-3 reaffirms ...

Cytisinicline treatment significantly increased the odds of smoking cessation and reduced nicotine cravings compared with placebo. Cytisinicline significantly increased the likelihood of quitting and ...

An incredibly rare albino orca was caught on camera leaping out of the ocean, leaving an impassioned wildlife photographer ...

The prior ORCA-V1 trial showed efficacy of cytisinicline for vapers looking to quit. For smokers, the ORCA-2 trial showed ...

They schedule it for you and check in regularly. Your job? Add salt every 3 or 4 months, which is cheap and easy to grab from ...

Similar to the first Phase 3 trial, ORCA-3 participants had an average age of 53 years, smoked a median of 20 cigarettes per day at baseline, and had a median smoking history of 36 years with four ...

Achieve Life Sciences (ACHV) announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association Internal Medicine.ORCA-3 was the second ...

(MENAFN- GlobeNewsWire - Nasdaq) ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline ...